PEG化医薬品市場調査レポート

Overview of the Market

During the assessment period, the PEGylated Drugs Market is expected to grow at a noteworthy CAGR of 5.17%. The process by which covalent and non-covalent glycol polymer chains bind to bioactive substances such proteins, peptides, enzymes, oligonucleotides, and antibody fragments is known as pegylation.  In a clinical setting, it is a safe method for boosting the therapeutic effectiveness of medications. Numerous FDA-approved pegylated medications are used in clinical settings.

評価期間中、PEG化医薬品市場は5.17%という注目すべきCAGRで成長すると予想されています。共有結合性および非共有結合性のグリコールポリマー鎖が、タンパク質、ペプチド、酵素、オリゴヌクレオチド、抗体断片などの生理活性物質に結合するプロセスは、PEG化として知られています。臨床現場では、PEG化は薬剤の治療効果を高める安全な方法です。FDA承認を受けたPEG化医薬品は数多く臨床現場で使用されています。

The global pegylated market is expanding due to the rising prevalence of chronic illnesses, developments in biologics, and newly approved pegylated medications. The market is also constrained by high production costs, regulatory obstacles, and possible adverse consequences. However, the industry will have future development prospects due to customized medicine, expanding markets, and cutting-edge drug delivery technologies.

The study includes a thorough analysis of the pegylated antibody’s advantages, market expansion, motivating factors, and difficulties. It also highlights the main players in the PEGylated Proteins Market, their contributions, and their advancements.

The development of biologics industries, the rise in the prevalence of diseases like cancer, and the expansion of pharmaceutical industries worldwide are the primary factors propelling the PEGylated Drugs Market. Furthermore, Canada’s rising rates of chronic illnesses and cancer-related deaths will support the expansion of pegylated medications on the market.

Overview of Market Segments

The PEGylated Drugs Market is divided into three segments: region, indication, and molecule.

The market has been divided into three segments based on molecules: liposomes, lipid nanoparticles (LNP), macromolecular drugs, and small molecular drugs.

The global market for pegylated pharmaceuticals has been divided into several segments based on their respective applications, including autoimmune diseases, neurology, oncology, and hematology.

The market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution route.

Analysis by region

The global market for PEGylated drugs has been divided into four segments based on geography: North America, Europe, Asia-Pacific, and the rest of the world. The greatest market share in 2024 was held by North America, which is expected to grow to USD 8,969.41 million by 2035. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.03%.

North America and South America make up the American market. The North American market is dominated by the United States and Canada. The market is expanding due to the increased occurrence of chronic illnesses like cancer.

The European government’s investment and assistance in the fight against chronic illnesses is what is propelling the regional market’s expansion. Western Europe and Eastern Europe are two further classifications for the European region. The United Kingdom, Italy, France, Spain, and the rest of Western Europe are also included in this category.

Key players

Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc., Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are the companies that are involved in the PEGylated Drugs Market.。

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY ……………………………………………………………………………………………….. 18

2 MARKET INTRODUCTION ……………………………………………………………………………………………… 20

2.1 DEFINITION …………………………………………………………………………………………………………………………. 20

2.2 SCOPE OF THE STUDY …………………………………………………………………………………………………………. 20

2.3 RESEARCH OBJECTIVE ………………………………………………………………………………………………………… 20

2.4 MARKET STRUCTURE ………………………………………………………………………………………………………….. 21

3 RESEARCH METHODOLOGY ………………………………………………………………………………………… 22

3.1 OVERVIEW …………………………………………………………………………………………………………………………… 22

3.2 DATA FLOW …………………………………………………………………………………………………………………………. 24

3.2.1 DATA MINING PROCESS ……………………………………………………………………………………………………. 24

3.3 PURCHASED DATABASE: …………………………………………………………………………………………………….. 25

3.4 SECONDARY SOURCES: ……………………………………………………………………………………………………….. 26

3.4.1 SECONDARY RESEARCH DATA FLOW: ………………………………………………………………………………….. 27

3.5 PRIMARY RESEARCH: ………………………………………………………………………………………………………….. 28

3.5.1 PRIMARY RESEARCH DATA FLOW: ……………………………………………………………………………………… 29

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ………………………………………………….. 30

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ………………………………………………………………………… 30

3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ………………………………………………………………… 31

3.6.1 REVENUE ANALYSIS APPROACH ………………………………………………………………………………………… 31

3.7 DATA FORECASTING …………………………………………………………………………………………………………… 32

3.7.1 DATA FORECASTING TYPE ………………………………………………………………………………………………… 32

3.8 DATA MODELING ………………………………………………………………………………………………………………… 33

3.8.1 MICROECONOMIC FACTOR ANALYSIS: ………………………………………………………………………………… 33

3.8.2 DATA MODELING:…………………………………………………………………………………………………………….. 34

3.9 TEAMS AND ANALYST CONTRIBUTION ……………………………………………………………………………… 37

4 MARKET DYNAMICS …………………………………………………………………………………………………….. 39

4.1 INTRODUCTION …………………………………………………………………………………………………………………… 39

4.2 DRIVERS ………………………………………………………………………………………………………………………………. 40

4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES …………………………………………………………………. 40

4.2.2 ADVANCEMENTS IN BIOLOGICS …………………………………………………………………………………………. 40

4.2.3 RECENTLY APPROVED PEGYLATED DRUGS …………………………………………………………………………… 40

4.3 RESTRAINTS …………………………………………………………………………………………………………………………. 42

4.3.1 HIGH PRODUCTION COSTS ………………………………………………………………………………………………… 42

4.3.2 REGULATORY HURDLES …………………………………………………………………………………………………….. 43

4.3.3 POTENTIAL SIDE EFFECTS…………………………………………………………………………………………………. 43

4.4 OPPORTUNITY …………………………………………………………………………………………………………………….. 44

4.4.1 EMERGING MARKETS ……………………………………………………………………………………………………….. 44

4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS ………………………………………………………………………………. 45

4.4.3 PERSONALIZED MEDICINE …………………………………………………………………………………………………. 45

5 MARKET FACTOR ANALYSIS ………………………………………………………………………………………… 46

5.1 PORTER’S FIVE FORCES MODEL ………………………………………………………………………………………….. 46

5.1.1 THREAT OF NEW ENTRANTS ……………………………………………………………………………………………… 46

5.1.2 BARGAINING POWER OF SUPPLIERS ……………………………………………………………………………………. 47

5.1.3 THREAT OF SUBSTITUTES …………………………………………………………………………………………………. 47

5.1.4 BARGAINING POWER OF BUYERS ………………………………………………………………………………………… 47

5.1.5 INTENSITY OF RIVALRY …………………………………………………………………………………………………….. 47

5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET ……………………………. 48

5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE …………………………………………………. 52

6.1 OVERVIEW …………………………………………………………………………………………………………………………… 52

6.2 MACROMOLECULAR DRUGS ………………………………………………………………………………………………. 54

6.2.1 PROTEIN AND PEPTIDE …………………………………………………………………………………………………….. 55

6.2.2 ENZYME ………………………………………………………………………………………………………………………… 56

6.2.3 APTAMER ………………………………………………………………………………………………………………………. 56

6.3 SMALL MOLECULAR DRUGS ……………………………………………………………………………………………….. 57

6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES ………………………………………………………………… 57

7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION ……………………………………………… 58

7.1 OVERVIEW …………………………………………………………………………………………………………………………… 58

7.2 ONCOLOGY ………………………………………………………………………………………………………………………….. 61

7.3 NEUROLOGY ………………………………………………………………………………………………………………………… 61

7.4 AUTOIMMUNE DISEASES …………………………………………………………………………………………………….. 62

7.5 HAEMATOLOGY ………………………………………………………………………………………………………………….. 62

7.6 OTHERS ………………………………………………………………………………………………………………………………… 63

8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL ……………………………. 64

8.1 OVERVIEW …………………………………………………………………………………………………………………………… 64

8.2 HOSPITAL PHARMACY ……………………………………………………………………………………………………….. 66

8.3 ONLINE PHARMACY ……………………………………………………………………………………………………………. 66

8.4 RETAIL PHARMACY …………………………………………………………………………………………………………….. 67

9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION ……………………………………………………… 68

9.1 OVERVIEW …………………………………………………………………………………………………………………………… 68

9.2 NORTH AMERICA ………………………………………………………………………………………………………………… 70

9.2.1 US ………………………………………………………………………………………………………………………………… 74

9.2.2 CANADA ………………………………………………………………………………………………………………………… 76

9.3 EUROPE ………………………………………………………………………………………………………………………………… 78

9.3.1 GERMANY ………………………………………………………………………………………………………………………. 82

9.3.2 FRANCE …………………………………………………………………………………………………………………………. 84

9.3.3 UK ………………………………………………………………………………………………………………………………… 85

9.3.4 ITALY …………………………………………………………………………………………………………………………….. 87

9.3.5 SPAIN ……………………………………………………………………………………………………………………………. 89

9.3.6 REST OF EUROPE …………………………………………………………………………………………………………….. 91

9.4 ASIA-PACIFIC ………………………………………………………………………………………………………………………. 93

9.4.1 CHINA …………………………………………………………………………………………………………………………… 96

9.4.2 INDIA …………………………………………………………………………………………………………………………….. 98

9.4.3 JAPAN …………………………………………………………………………………………………………………………… 100

9.4.4 AUSTRALIA …………………………………………………………………………………………………………………….. 101

9.4.5 SOUTH KOREA ………………………………………………………………………………………………………………… 103

9.4.6 REST OF ASIA-PACIFIC ……………………………………………………………………………………………………… 104

9.5 REST OF THE WORLD ………………………………………………………………………………………………………….. 107

9.5.1 MIDDLE EAST & AFRICA ……………………………………………………………………………………………………. 110

9.5.2 SOUTH AMERICA……………………………………………………………………………………………………………… 112

9.5.2.1 BRAZIL ……………………………………………………………………………………………………………………. 114

9.5.2.2 MEXICO …………………………………………………………………………………………………………………… 115

9.5.2.3 ARGENTINA ……………………………………………………………………………………………………………… 117

9.5.2.4 REST OF SOUTH AMERICA ………………………………………………………………………………………….. 119

10 COMPETITIVE LANDSCAPE ………………………………………………………………………………………….. 122

10.1 INTRODUCTION …………………………………………………………………………………………………………………… 122

10.2 MARKET SHARE ANALYSIS, 2024 ………………………………………………………………………………………… 122

10.3 COMPETITOR DASHBOARD ………………………………………………………………………………………………… 123

10.4 PUBLIC PLAYERS STOCK SUMMARY …………………………………………………………………………………… 124

10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL …………………………………………………………. 125

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ………………………………………………………………… 126

10.6.1 PRODUCT APPROVAL ……………………………………………………………………………………………………….. 126

10.6.2 PRODUCT EXPANSION ……………………………………………………………………………………………………… 127

10.6.3 APPROVAL DENIED ………………………………………………………………………………………………………….. 127

10.6.4 PRODUCT DISCONTINUATION…………………………………………………………………………………………….. 127

10.6.5 AGREEMENT/ACQUISITION ……………………………………………………………………………………………….. 128

10.6.6 CLINICAL TRIAL FINDINGS ………………………………………………………………………………………………… 128

11 COMPANY PROFILES …………………………………………………………………………………………………… 129

11.1 AMGEN INC. …………………………………………………………………………………………………………………………. 129

11.1.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 129

11.1.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 130

11.1.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 131

11.1.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 131

11.1.5 SWOT ANALYSIS ……………………………………………………………………………………………………………… 132

11.1.6 KEY STRATEGIES …………………………………………………………………………………………………………….. 132

11.2 PFIZER INC. ………………………………………………………………………………………………………………………….. 133

11.2.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 133

11.2.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 135

11.2.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 136

11.2.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 136

11.2.5 SWOT ANALYSIS ……………………………………………………………………………………………………………… 136

11.2.6 KEY STRATEGIES …………………………………………………………………………………………………………….. 137

11.3 BIOGEN ………………………………………………………………………………………………………………………………… 138

11.3.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 138

11.3.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 139

11.3.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 140

11.3.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 140

11.3.5 KEY STRATEGIES …………………………………………………………………………………………………………….. 140

11.4 BAYER AG …………………………………………………………………………………………………………………………….. 141

11.4.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 141

11.4.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 142

11.4.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 142

11.4.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 143

11.4.5 SWOT ANALYSIS ……………………………………………………………………………………………………………… 143

11.4.6 KEY STRATEGY ……………………………………………………………………………………………………………….. 144

11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED…………………………………………………………….. 145

11.5.1 COMPANY OVERVIEW ……………………………………………………………………………………………………… 145

11.5.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 146

11.5.3 PRODUCT OFFERED ………………………………………………………………………………………………………….. 146

11.5.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 147

11.5.5 KEY STRATEGIES …………………………………………………………………………………………………………….. 147

11.6 NOVO NORDISK A/S …………………………………………………………………………………………………………….. 148

11.6.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 148

11.6.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 149

11.6.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 150

11.6.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 150

11.6.5 SWOT ANALYSIS ……………………………………………………………………………………………………………… 151

11.6.6 KEY STRATEGIES …………………………………………………………………………………………………………….. 151

11.7 SANDOZ GROUP AG …………………………………………………………………………………………………………….. 152

11.7.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 152

11.7.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 153

11.7.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 154

11.7.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 154

11.7.5 KEY STRATEGIES …………………………………………………………………………………………………………….. 154

11.8 ASTRAZENECA …………………………………………………………………………………………………………………….. 155

11.8.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 155

11.8.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 156

11.8.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 157

11.8.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 157

11.8.5 KEY STRATEGIES …………………………………………………………………………………………………………….. 157

11.9 COHERUS BIOSCIENCES, INC. ……………………………………………………………………………………………… 158

11.9.1 COMPANY OVERVIEW ………………………………………………………………………………………………………. 158

11.9.2 FINANCIAL OVERVIEW………………………………………………………………………………………………………. 159

11.9.3 PRODUCTS OFFERED ………………………………………………………………………………………………………… 160

11.9.4 KEY DEVELOPMENTS ……………………………………………………………………………………………………….. 160

11.9.5 KEY STRATEGIES …………………………………………………………………………………………………………….. 160

11.10 F. HOFFMANN-LA ROCHE LTD. …………………………………………………………………………………………… 161

11.10.1 COMPANY OVERVIEW ……………………………………………………………………………………………. 161

11.10.2 FINANCIAL OVERVIEW …………………………………………………………………………………………… 162

11.10.3 PRODUCTS OFFERED …………………………………………………………………………………………….. 163

11.10.4 KEY DEVELOPMENTS …………………………………………………………………………………………….. 163

11.10.5 SWOT ANALYSIS ………………………………………………………………………………………………….. 163

11.10.6 KEY STRATEGIES ………………………………………………………………………………………………….. 164

11.11 JOHNSON & JOHNSON INC. …………………………………………………………………………………………………. 165

11.11.1 COMPANY OVERVIEW ……………………………………………………………………………………………. 165

11.11.2 FINANCIAL OVERVIEW …………………………………………………………………………………………… 166

11.11.3 PRODUCTS OFFERED …………………………………………………………………………………………….. 167

11.11.4 KEY DEVELOPMENTS …………………………………………………………………………………………….. 167

11.11.5 SWOT ANALYSIS ………………………………………………………………………………………………….. 167

11.11.6 KEY STRATEGIES ………………………………………………………………………………………………….. 168

11.12 ALNYLAM PHARMACEUTICALS, INC. …………………………………………………………………………………. 169

11.12.1 COMPANY OVERVIEW ……………………………………………………………………………………………. 169

11.12.2 FINANCIAL OVERVIEW …………………………………………………………………………………………… 170

11.12.3 PRODUCTS OFFERED …………………………………………………………………………………………….. 170

11.12.4 KEY DEVELOPMENTS …………………………………………………………………………………………….. 171

11.12.5 KEY STRATEGIES ………………………………………………………………………………………………….. 171

11.13 LES LABORATOIRES SERVIER ……………………………………………………………………………………………… 172

11.13.1 COMPANY OVERVIEW ……………………………………………………………………………………………. 172

11.13.2 FINANCIAL OVERVIEW …………………………………………………………………………………………… 172

11.13.3 PRODUCT OFFERED ………………………………………………………………………………………………. 173

11.13.4 KEY DEVELOPMENTS …………………………………………………………………………………………….. 173

11.13.5 KEY STRATEGIES ………………………………………………………………………………………………….. 173

12 DATA CITATIONS …………………………………………………………………………………………………………. 174

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34

TABLE 2 RECENTLY APPROVED PEGYLATED DRUGS IN U.S., AUSTRALIA, JAPAN, AND CANADA 41

TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 53

TABLE 4 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 54

TABLE 5 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 55

TABLE 6 GLOBAL PEGYLATED DRUGS MARKET, FOR PROTEIN AND PEPTIDE, BY REGION, 2019–2035 (USD MILLION) 55

TABLE 7 GLOBAL PEGYLATED DRUGS MARKET, FOR ENZYME, BY REGION, 2019–2035 (USD MILLION) 56

TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, FOR APTAMER, BY REGION, 2019–2035 (USD MILLION) 56

TABLE 9 GLOBAL PEGYLATED DRUGS MARKET, FOR SMALL MOLECULAR DRUGS, BY REGION, 2019–2035 (USD MILLION) 57

TABLE 10 GLOBAL PEGYLATED DRUGS MARKET, FOR LIPID NANOPARTICLES (LNP) AND LIPOSOMES, BY REGION, 2019–2035 (USD MILLION) 57

TABLE 11 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 60

TABLE 12 GLOBAL PEGYLATED DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD MILLION) 61

TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, FOR NEUROLOGY, BY REGION, 2019–2035 (USD MILLION) 61

TABLE 14 GLOBAL PEGYLATED DRUGS MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2035 (USD MILLION) 62

TABLE 15 GLOBAL PEGYLATED DRUGS MARKET, FOR HAEMATOLOGY, BY REGION, 2019–2035 (USD MILLION) 62

TABLE 16 GLOBAL PEGYLATED DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 63

TABLE 17 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 65

TABLE 18 GLOBAL PEGYLATED DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66

TABLE 19 GLOBAL PEGYLATED DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2035 (USD MILLION) 66

TABLE 20 GLOBAL PEGYLATED DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2035 (USD MILLION) 67

TABLE 21 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2019–2035 (USD MILLION) 69

TABLE 22 NORTH AMERICA PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 71

TABLE 23 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 72

TABLE 24 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 73

TABLE 25 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 73

TABLE 26 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 74

TABLE 27 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 74

TABLE 28 US: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 74

TABLE 29 US: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 75

TABLE 30 US: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 75

TABLE 31 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 76

TABLE 32 CANADA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 76

TABLE 33 CANADA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77

TABLE 34 CANADA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 77

TABLE 35 EUROPE PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 79

TABLE 36 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 80

TABLE 37 EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 80

TABLE 38 EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 81

TABLE 39 EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 81

TABLE 40 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 82

TABLE 41 GERMANY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 82

TABLE 42 GERMANY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83

TABLE 43 GERMANY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 83

TABLE 44 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 84

TABLE 45 FRANCE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 84

TABLE 46 FRANCE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 84

TABLE 47 FRANCE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 85

TABLE 48 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 85

TABLE 49 UK: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 86

TABLE 50 UK: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 86

TABLE 51 UK: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 86

TABLE 52 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 87

TABLE 53 ITALY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 87

TABLE 54 ITALY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 88

TABLE 55 ITALY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 88

TABLE 56 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 89

TABLE 57 SPAIN: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 89

TABLE 58 SPAIN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 90

TABLE 59 SPAIN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 90

TABLE 60 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 91

TABLE 61 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 91

TABLE 62 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 92

TABLE 63 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 92

TABLE 64 ASIA-PACIFIC PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 94

TABLE 65 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 95

TABLE 66 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 95

TABLE 67 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95

TABLE 68 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 96

TABLE 69 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 96

TABLE 70 CHINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 97

TABLE 71 CHINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 97

TABLE 72 CHINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 97

TABLE 73 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 98

TABLE 74 INDIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 98

TABLE 75 INDIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 99

TABLE 76 INDIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 99

TABLE 77 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 100

TABLE 78 JAPAN: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 100

TABLE 79 JAPAN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 100

TABLE 80 JAPAN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 101

TABLE 81 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 101

TABLE 82 AUSTRALIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 102

TABLE 83 AUSTRALIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102

TABLE 84 AUSTRALIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 102

TABLE 85 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 103

TABLE 86 SOUTH KOREA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 103

TABLE 87 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104

TABLE 88 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 104

TABLE 89 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 104

TABLE 90 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 105

TABLE 91 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 105

TABLE 92 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 106

TABLE 93 REST OF THE WORLD PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 108

TABLE 94 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 108

TABLE 95 REST OF THE WORLD: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 109

TABLE 96 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109

TABLE 97 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 109

TABLE 98 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 110

TABLE 99 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 110

TABLE 100 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111

TABLE 101 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 111

TABLE 102 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 112

TABLE 103 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 112

TABLE 104 SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 112

TABLE 105 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113

TABLE 106 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 113

TABLE 107 BRAZIL: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 114

TABLE 108 BRAZIL: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 114

TABLE 109 BRAZIL: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115

TABLE 110 BRAZIL: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 115

TABLE 111 MEXICO: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 115

TABLE 112 MEXICO: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 116

TABLE 113 MEXICO: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116

TABLE 114 MEXICO: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 117

TABLE 115 ARGENTINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 117

TABLE 116 ARGENTINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 117

TABLE 117 ARGENTINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 118

TABLE 118 ARGENTINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 118

TABLE 119 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019–2035 (USD MILLION) 119

TABLE 120 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019–2035 (USD MILLION) 119

TABLE 121 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 120

TABLE 122 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 120

TABLE 123 PRODUCT APPROVAL 126

TABLE 124 PRODUCT EXPANSION 127

TABLE 125 APPROVAL DENIED 127

TABLE 126 PRODUCT DISCONTINUATION 127

TABLE 127 AGREEMENT/ACQUISITION 128

TABLE 128 CLINICAL TRIAL FINDINGS 128

TABLE 129 AMGEN INC.: PRODUCTS OFFERED 131

TABLE 130 AMGEN INC.: KEY DEVELOPMENTS 131

TABLE 131 PFIZER INC.: PRODUCTS OFFERED 136

TABLE 132 PFIZER INC.: KEY DEVELOPMENTS 136

TABLE 133 BIOGEN: PRODUCTS OFFERED 140

TABLE 134 BIOGEN: KEY DEVELOPMENTS 140

TABLE 135 BAYER AG: PRODUCTS OFFERED 142

TABLE 136 BAYER AG: KEY DEVELOPMENTS 143

TABLE 137 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 146

TABLE 138 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS 147

TABLE 139 NOVO NORDISK A/S: PRODUCTS OFFERED 150

TABLE 140 NOVO NORDISK A/S: KEY DEVELOPMENTS 150

TABLE 141 SANDOZ GROUP AG: PRODUCTS OFFERED 154

TABLE 142 SANDOZ GROUP AG: KEY DEVELOPMENTS 154

TABLE 143 ASTRAZENECA: PRODUCTS OFFERED 157

TABLE 144 ASTRAZENECA: KEY DEVELOPMENTS 157

TABLE 145 COHERUS BIOSCIENCES, INC.: PRODUCTS OFFERED 160

TABLE 146 COHERUS BIOSCIENCES, INC.: KEY DEVELOPMENTS 160

TABLE 147 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 163

TABLE 148 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED 167

TABLE 149 ALNYLAM PHARMACEUTICALS, INC: PRODUCTS OFFERED 170

TABLE 150 ALNYLAM PHARMACEUTICALS, INC: KEY DEVELOPMENTS 171

TABLE 151 LES LABORATOIRES SERVIER: PRODUCTS OFFERED 173

LIST OF FIGURES

FIGURE 1 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE 21

FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) 39

FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035) 42

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035) 44

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL PEGYLATED DRUGS MARKET 46

FIGURE 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2024 & 2035 (USD MILLION) 53

FIGURE 7 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY MOLECULE, 2024 54

FIGURE 8 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 59

FIGURE 9 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY APPLICATION, 2024 60

FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION) 64

FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 65

FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD MILLION) 68

FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 (%) 69

FIGURE 14 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 71

FIGURE 15 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 72

FIGURE 16 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 78

FIGURE 17 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 79

FIGURE 18 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 93

FIGURE 19 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 94

FIGURE 20 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 107

FIGURE 21 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 108

FIGURE 22 GLOBAL PEGYLATED DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 122

FIGURE 23 COMPETITOR DASHBOARD: GLOBAL PEGYLATED DRUGS MARKET 123

FIGURE 24 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 130

FIGURE 25 AMGEN INC.: SWOT ANALYSIS 132

FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 135

FIGURE 27 PFIZER INC.: SWOT ANALYSIS 136

FIGURE 28 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT 139

FIGURE 29 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 142

FIGURE 30 BAYER AG: SWOT ANALYSIS 143

FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT 146

FIGURE 32 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 149

FIGURE 33 NOVO NORDISK A/S: SWOT ANALYSIS 151

FIGURE 34 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT 153

FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 156

FIGURE 36 COHERUS BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT 159

FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 162

FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 163

FIGURE 39 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 166

FIGURE 40 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 167

FIGURE 41 ALNYLAM PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT 170

Market Research Future（マーケットリサーチフューチャー）はインドに主拠点を置き、技術的および経済的進歩に関して貴重な分析とデータを提供しています。調査結果にはMarket Research Futureのアナリストが直接著名な市場プレーヤーから入手した関連情報も含まれています。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
パターン1

パターン2

ご購入に関するご案内

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。
  • 手数料はいただいておりません。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルの閲覧・レポート内容の利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連企業除く）10名までレポートファイルのご共有可能です。
  • エンタープライズワイドライセンス
    • 同一企業であれば、人数無制限でレポートファイルの閲覧・レポート内容の利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後2営業日以内
• その他
  • 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

レポートの詳細、価格、購入等に関するご質問はいつでもお気軽にお問合せください。

最新調査レポート

• 埋め込み型ポート市場調査レポート
• テレマティクス市場調査レポート
• トラック・バス用タイヤ市場調査レポート
• ヘリウム3市場調査レポート
• メインフレーム市場調査レポート

Market Research Future 出版レポート一覧